Our research is driven by a distinctive scientific and clinical strategy focused
on precision oncology — understanding how cancer develops on a genomic level and developing drugs that hone in on those targets.
Not exact matches
Many scientists now believe that — complementing its initial focus
on mutated genes —
precision oncology must now also address the activity of otherwise normal proteins and molecular pathways that are ultimately responsible for cancer cells» malignant behavior.
Our groundbreaking Pediatric Mi - Oncoseq Program is an internationally known
precision oncology program focusing
on the genetic analysis of pediatric cancer patients including in children with malignant brain tumors, and determines whether targeted treatments may be available based upon their personalized tumor genomic sequencing profiles.
Team collaboration launch of Target Now Registry aimed to act as a robust information catalyst, advancing
precision medicine in
oncology through the broad - based acquisition and sharing of valuable molecular, clinical and outcomes data, while collaborating
on a national level in a secure, community - based environment.